An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

This study aims to evaluate the safety and efficacy of MT-3995 administered over the longer term, following MT-3995-J05 study.

Inclusion Criteria:

• Written informed consent for participation before the completion of MT-3995-J05 Study
• Completion of MT-3995-J05 study

Exclusion Criteria:

• UACR of ≥300 mg/g Cr with an increase of ≥30% in MT-3995-J05 Study
• Symptomatic and clinically significant hypotension
• QT prolongation or torsades de pointes
• New York Heart Association (NYHA) Class III or IV heart failure
• Patients who are judged to be unsuitable for participation based on their safety profile in MT-3995-J05 Study